Seracare Life Sciences (SRLS)
Seracare Life Sciences Market Cap: 80.64M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SRLS Market Cap Rankings
| Overall | 21st percentile | 3684 of 4664 |
| Sector | 27th percentile | 382 of 527 in Healthcare |
| Industry | 21st percentile | 11 of 14 in Drugs - Generic |
SRLS Market Cap Range, Past 5 Years
| Minimum | 8.361M | Mar 2009 |
| Maximum | 124.22M | Jun 2007 |
| Average | 70.10M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these SRLS related companies
SRLS News
UPDATE: Dawson James Securities Downgrades SeraCare Life Sciences to Neutral
Mar 05, 10:42AM Benzinga
Mar 05, 10:42AM Benzinga
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Seracare Life Sciences, Inc.
Feb 29, 5:00PM Business Wire
Feb 29, 5:00PM Business Wire
Goldfarb LLP Securities Lawyers Seek More Money, Information for Shareholders in SeraCare Life Sciences Buyout
Feb 23, 10:00AM PR Newswire
Feb 23, 10:00AM PR Newswire
Bull & Lifshitz, LLP Announces Investigation of SeraCare Life Sciences, Inc.
Feb 18, 9:00AM PR Newswire
Feb 18, 9:00AM PR Newswire
The Law Firm of Weiss & Lurie Investigates SeraCare Life Sciences, Inc.
Feb 15, 5:21PM Business Wire
Feb 15, 5:21PM Business Wire
Robbins Umeda LLP Announces an Investigation of SeraCare Life Sciences, Inc.
Feb 15, 1:05PM Business Wire
Feb 15, 1:05PM Business Wire
Law Office of Brodsky & Smith, LLC Announces Investigation of SeraCare Life Sciences, Inc.
Feb 15, 12:41PM Business Wire
Feb 15, 12:41PM Business Wire
Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of SeraCare Life Sciences
Feb 14, 11:42AM Business Wire
Feb 14, 11:42AM Business Wire
Ryan & Maniskas, LLP Announces Investigation of SeraCare Life Sciences Inc.
Feb 14, 11:09AM Business Wire
Feb 14, 11:09AM Business Wire
Law Offices of Howard G. Smith Announces Investigation of SeraCare Life Sciences, Inc.
Feb 13, 7:00PM Business Wire
Feb 13, 7:00PM Business Wire
Law Office of Brodsky & Smith, LLC Announces Investigation of SeraCare Life Sciences, Inc.
Feb 13, 4:08PM PR Newswire
Feb 13, 4:08PM PR Newswire
Glancy Binkow & Goldberg LLP Announces Investigation of SeraCare Life Sciences, Inc.
Feb 13, 12:20PM Business Wire
Feb 13, 12:20PM Business Wire
Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeraCare Life Sciences, Inc.
Feb 13, 11:28AM Business Wire
Feb 13, 11:28AM Business Wire
SeraCare Announces Definitive Agreement to be Acquired by Linden Capital Partners
Feb 13, 6:46AM PR Newswire
Feb 13, 6:46AM PR Newswire
SeraCare Life Sciences, Inc. (SRLS) Tops Q1 EPS by 3c, Sales Top Expectations
Feb 10, 7:04AM Street Insider
Feb 10, 7:04AM Street Insider
SeraCare Reports 9 Percent Revenue Growth in First Quarter Fiscal Year 2012
Feb 10, 7:03AM PR Newswire
Feb 10, 7:03AM PR Newswire
SeraCare Expands Infectious Disease Offerings with Six New Product Introductions
Feb 09, 8:04AM Benzinga
Feb 09, 8:04AM Benzinga
SeraCare Life Sciences to Report First Quarter Fiscal Year 2012 Financial Results on February 10, 2012
Feb 07, 2:14PM PR Newswire
Feb 07, 2:14PM PR Newswire
SeraCare Life Sciences to Report Fourth Quarter and Fiscal Year 2011 Results on November 17, 2011
Nov 14, 8:33AM PR Newswire
Nov 14, 8:33AM PR Newswire
Lazard Capital Initiated Coverage on SeraCare Life Sciences $SRLS with a Buy. Stock up nicely today.
about 610 days ago by BioMedReports
about 610 days ago by BioMedReports
SeraCare Life Sciences $SRLS insider buying in last two days - Client
about 652 days ago by macbiocom
about 652 days ago by macbiocom
$SRLS bouncing off its 50 day ma and now challenging its 10 day ma on the upside
about 721 days ago by stocktilludrop
about 721 days ago by stocktilludrop
Another great quarter for SeraCare Life Sciences $SRLS - Revenues up 18% - $.11/shr earnings
about 763 days ago by macbiocom
about 763 days ago by macbiocom
SeraCare LifeSciences - $SRLS - great turn around story. 1,200% stock increase since 52 week low.
about 923 days ago by macbiocom
about 923 days ago by macbiocom
Top NASDAQ Gainers heading into close: $PLCC $ZOOM $SRLS $CPBK $ADCT #stocks http://bit.ly/Kls0X
about 1023 days ago by QualityStocks
about 1023 days ago by QualityStocks
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SRLS | 4.01 | +0.00 | +0.00% | 80.64M |
| SRI | 7.02 | +0.07 | +1.01% | 195.50M |
| SREV | 12.07 | +0.03 | +0.25% | 891.92M |
| SRE | 65.34 | +0.79 | +1.22% | 15.54B |
| SRDX | 13.85 | -0.10 | -0.72% | 244.68M |
| SRCE | 21.42 | +0.20 | +0.94% | 536.44M |
| SR | 0.675 | -0.00 | -0.72% | 20.36M |
| SQQQ | 53.14 | +0.08 | +0.15% | |
| SQNS | 2.16 | -0.01 | -0.46% | 75.23M |
| SQNM | 3.84 | -0.24 | -5.88% | 467.32M |